Drug Eluting Stent News and Research

RSS

A drug-eluting stent (DES) is a coronary stent (a scaffold) placed into narrowed, diseased coronary arteries that slowly releases a drug to block cell proliferation. This prevents fibrosis that, together with clots (thrombus), could otherwise block the stented artery, a process called restenosis.

Hybrid revascularization procedure is safe and feasible for left main coronary artery stenosis

The left main coronary artery provides most of the blood to the heart, and current guidelines call for patients with blockages in this artery to undergo bypass surgery.

16 Mar 2010

PERSEUS clinical program demonstrates positive results of TAXUS Element Paclitaxel-Eluting Stent System

Boston Scientific Corporation today announced 12-month results from its PERSEUS clinical program that demonstrated positive safety and efficacy outcomes in workhorse lesions for the platinum chromium TAXUS® Element™ Paclitaxel-Eluting Stent System compared to the TAXUS® Express2™ Paclitaxel-Eluting Stent System.

16 Mar 2010

Medtronic' Endeavor DES demonstrates safety and efficacy profile for coronary artery disease treatment

The consistency and quality of the long-term clinical results for the Endeavor® drug-eluting stent (DES) from Medtronic, Inc., continue to distinguish it as a treatment for coronary artery disease, according to newly released data.

16 Mar 2010

Drug-eluting stents offer new hope to patients with critical limb ischemia

In the United States, more than 100,000 amputations are performed each year on individuals with critical limb ischemia, the most severe form of peripheral arterial disease (PAD). The number one priority in treating these patients is to re-establish blood flow to avoid limb amputation.

16 Mar 2010

New trial comparing drug-eluting stents to bypass graft surgery in left main coronary artery disease patients

The announcement of a new clinical trial, EXCEL (Evaluation of Xience Prime versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization), that will compare drug-eluting stents to coronary artery bypass graft surgery in patients with left main coronary artery disease, was made today at "Optimizing PCI Outcomes: Evolving Paradigms," a symposium presented by the Cardiovascular Research Foundation.

15 Mar 2010

Tryton Medical announces implantation of Tryton stent for the first time in Portugal and Austria

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced that the Tryton® stent has been implanted for the first time in Portugal and Austria.

19 Feb 2010

Boston Scientific reports fourth quarter and full year 2009 results

Boston Scientific Corporation today announced financial results for the fourth quarter and full year ended December 31, 2009, as well as guidance for net sales and earnings per share (EPS) for the first quarter and full year 2010.

10 Feb 2010

Abbott declares quarterly dividend of 40 cents per share

Abbott today announced financial results for the fourth quarter ended Dec. 31, 2009.

27 Jan 2010

Cook Medical presents latest advancements at ISET 2010 International Symposium on Endovascular Therapy

Signaling its continued commitment to addressing the anatomy of the entire peripheral vasculature and combating disease with targeted diagnostic and interventional devices, Cook Medical is presenting its latest advancements at the ISET 2010 International Symposium on Endovascular Therapy.

20 Jan 2010

Svelte Medical Systems initiates European clinical trial for SOAW delivery system

Svelte Medical Systems, Inc. is pleased to announce that it has initiated its European clinical trial at the Thoraxcenter Research Center in Rotterdam, the Netherlands for its “Stent-on-a-Wire” (SOAW) cobalt–chromium Bare Metal Stent.

9 Jan 2010

Boston Scientific's PROMUS Everolimus-Eluting Coronary Stent System receives Japanese marketing approval

Boston Scientific Corporation announced today that it has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market its PROMUS® Everolimus-Eluting Coronary Stent System for the treatment of coronary artery disease. The Company plans to launch the product as soon as reimbursement approval is granted, which is expected in the coming weeks.

9 Jan 2010

Japanese MHLW approves Abbott's XIENCE V Everolimus Eluting Coronary Stent System

Abbott announced today that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved its XIENCE V® Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease.

8 Jan 2010

Sinexus renamed as Intersect ENT; begins clinical study on new bioabsorbable stent

Sinexus has changed its name to Intersect ENT. Intersect's initial focus is a bioabsorbable drug eluting stent to treat patients with chronic sinusitis, a debilitating condition that affects 37 million people each year and is more prevalent than heart disease or asthma.

8 Jan 2010

Boston Scientific commences enrollment in its TAXUS Liberte Stent System study

Boston Scientific Corporation today announced that it has enrolled the first patient in its TAXUS Liberte post-approval study. The study is designed to evaluate real-world clinical outcomes data for the TAXUS® Liberte® Paclitaxel-Eluting Coronary Stent System in combination with a dual antiplatelet therapy drug regimen that includes aspirin and Effient®, a new antiplatelet medication. Co-sponsors of the study include Eli Lilly and Company and Daiichi Sankyo, Inc., manufacturers of Effient, which was recently approved by the U.S. Food and Drug Administration (FDA).

4 Jan 2010

MRG: Chinese drug-eluting stent market to reach more than $900 million by 2014

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, health care reforms in China supported rapid expansion of the Chinese drug-eluting stent market in 2009, and will continue to fuel growth in the coming years.

17 Dec 2009

TRYTON-LM clinical study enrolls first two patients

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced the enrollment of the first two patients in TRYTON-LM, a prospective, single-arm study evaluating the feasibility of the Tryton stent in conjunction with Abbott’s XIENCE PRIME Everolimus Eluting Coronary Stent System to treat stable patients with complex de novo bifurcation lesions involving the left main coronary artery.

9 Dec 2009

Second-quarter fiscal 2010 results announced by Medtronic

Medtronic, Inc. today announced financial results for its second quarter of fiscal year 2010, which ended Oct. 30, 2009.

24 Nov 2009

Third-quarter financial results of Boston Scientific announced

Boston Scientific Corporation today announced financial results for the third quarter ended September 30, 2009, as well as guidance for net sales and earnings per share (EPS) for the fourth quarter and full year 2009.

20 Oct 2009

Medtronic commences study of the Zotarolimus-Eluting Peripheral Stent System for treating erectile dysfunction

Medtronic, Inc., announced today the initiation of a feasibility study of an interventional treatment for erectile dysfunction (ED) that uses a specially-designed drug-eluting stent system.

14 Oct 2009

Novasys Medical's Renessa named the most promising new product for 2009

Novasys Medical, Inc., a developer of innovative therapies in women's health, announced today that its Renessa® non-surgical treatment for female stress urinary incontinence (SUI) was inducted into the Phoenix Hall of Fame as the 2009 Most Promising New Product at the Phoenix Medical Device and Diagnostic Conference for Chief Executive Officers.

14 Oct 2009

Drug Eluting Stent News and Research

Further Reading

Hybrid revascularization procedure is safe and feasible for left main coronary artery stenosis

PERSEUS clinical program demonstrates positive results of TAXUS Element Paclitaxel-Eluting Stent System

Medtronic' Endeavor DES demonstrates safety and efficacy profile for coronary artery disease treatment

Drug-eluting stents offer new hope to patients with critical limb ischemia

New trial comparing drug-eluting stents to bypass graft surgery in left main coronary artery disease patients

Tryton Medical announces implantation of Tryton stent for the first time in Portugal and Austria

Boston Scientific reports fourth quarter and full year 2009 results

Abbott declares quarterly dividend of 40 cents per share

Cook Medical presents latest advancements at ISET 2010 International Symposium on Endovascular Therapy

Svelte Medical Systems initiates European clinical trial for SOAW delivery system

Boston Scientific's PROMUS Everolimus-Eluting Coronary Stent System receives Japanese marketing approval

Japanese MHLW approves Abbott's XIENCE V Everolimus Eluting Coronary Stent System

Sinexus renamed as Intersect ENT; begins clinical study on new bioabsorbable stent

Boston Scientific commences enrollment in its TAXUS Liberte Stent System study

MRG: Chinese drug-eluting stent market to reach more than $900 million by 2014

TRYTON-LM clinical study enrolls first two patients

Second-quarter fiscal 2010 results announced by Medtronic

Third-quarter financial results of Boston Scientific announced

Medtronic commences study of the Zotarolimus-Eluting Peripheral Stent System for treating erectile dysfunction

Novasys Medical's Renessa named the most promising new product for 2009

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News